The federal government is attempting to ensure that doctors don’t inadvertently compromise patient data when they use smartphones to access electronic health records.
The National Institutes of Standards in Technology this week released a step-by-step guide for hospitals and IT professionals, listing ways to secure the connection between devices and electronic health records.
The shift from fully integrated pharmaceutical companies (FIPCOs) to virtually integrated pharma companies (VIPCOs) has made biopharmas more reliant on external R&D. Often, that external R&D comes from startups nurtured through the venture funds of biopharma giants.
This year’s List offers three significant changes since last year’s ranking of corporate venture funds. One is the exclusion of Novo Ventures and Novo Seeds from the list, since the funds do not invest for the benefit for Novo Nordisk, but for its holding company Novo A/S.
Baxalta Incorporated, a $6 billion global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has completed the acquisition of the Oncaspar (pegaspargase) portfolio from Sigma-Tau Finanziaria S.p.A.
The acquisition includes Oncaspar, an important biologic treatment for patients with acute lymphoblastic leukemia (ALL), the novel investigational biologic calaspargase pegol, and established global clinical and commercial resources. Baxalta previously announced plans to acquire the portfolio for approximately $900 million.
Wednesday, August 5, 2015 from 5:00 PM to 7:00 PM (EDT)
The Washington DC region is part of an east coast corridor rich in life science talent, technical know-how and business development expertise. Montgomery County, Maryland itself is host to a unique ecosystem of potential resources for startups in health tech: centers of research, strong universities, leading biotech and pharma companies, and government agencies. This ecosystem means that health tech founders can immediately access resources and build the strategic partnerships to support their rapid growth.
This event will discuss Relevant Health, a new health tech startup accelerator program based in Rockville, Maryland, and the regional environment for startups in health tech. Come ready both to hear about opportunities for startups and discuss your experiences and needs as someone interested in building our health tech capital.
AstraZeneca’s global biologics R&D arm MedImmune has entered into a five-year multi-project research collaboration with the University of Sheffield to carry out breakthrough research in cell factory technology process.
With the in cell factory technology, living cells can be controlled and manipulated to make specific proteins with therapeutic benefits.
Johns Hopkins University tops the list of private, non-government employers in the Baltimore region, although three of the top five Baltimore-area employers are health systems — an unsurprising fact given that most workers in the Baltimore area are in health care or education.
Health care and education employees make up 19 percent of workers in the Baltimore area, more than any other supersector, according to May data from the U.S. Bureau of Labor Statistics. Still, there are large employers of many different industry types in the Baltimore area. Subscribers can check out the full list here.
MedImmune, the global biologics research and development arm of AstraZeneca, and the University of Sheffield announced today that they have entered into a multi-project research collaboration to generate breakthrough research in cell factory technology, the process by which living cells can be controlled and manipulated to make specific proteins with therapeutic benefits.
As part of the five-year collaboration, MedImmune will provide funding and in-kind contributions to support University of Sheffield post-doctoral and doctoral research projects to address key challenges in cell engineering. The aim is to produce tools to ensure that manufacturing success is “designed in” from a much earlier stage than occurs with current screening-based strategies, to improve the development and production of biologic medicines. The collaboration will focus on harnessing expertise from both MedImmune and the world-leading group in the University’s Advanced Biomanufacturing Centre to advance research specifically in mammalian cell factories.
Bioscience companies up to 7 years old can now apply for state funding that was formerly available only to younger companies.
BioInnovation Connecticut, managed by Connecticut Innovations, a state financing entity, invests in bioscience companies to speed the path to commercialization through its CT Bioscience Innovation Fund. Until July 1, only companies 3 years old and younger were eligible to apply, said Margaret Cartiera, vice president and fund manager for BioInnovation CT.
It is no secret that 2015 has been a highly active year for deal-making in the life science space. However, what is often overlooked is exactly where in the space those deals are taking place. Life Science Nation’s financing rounds database contains detailed information on over 250 of these rounds that have taken place since January 1 of 2015. We track this data from a variety of sources however as many companies and investors chose not to disclose this information this should be viewed as a sample of the entire data set of financings. With this article will highlight what our data tells us about the rounds that have taken place thus far in 2015 for therapeutics companies around the globe.
Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year to date total to almost $4B(covered here, here). Four of the last five quarters are amongst the largest record-setting quarters in ten years.
It’s one of the best periods for biotech funding in the history of the industry, offering an opportunity for emerging companies to scale and develop their pipelines more significantly than ever before.
